特瑞普利单抗联合卡培他滨化疗方案治疗晚期胃癌及对FOXA2、p27kip1表达水平影响

Effect of Triplelizumab Combined with XELOX in the Treatment of Ad⁃vanced Gastric Cancer and Expression Levels of FOXA2 and p27kip1

目的研究探讨特瑞普利单抗联合卡培他滨化疗方案(XELOX)治疗晚期胃癌及对叉头框蛋白A2(recombinant forkhead box protein A2,FOXA2)及细胞周期素依赖的蛋白激酶抑制物(cyclin dependent protein kinase inhibitor,p27kip1)表达水平影响。方法非随机选取2022年1月—2023年12月牡丹江医科大学附属红旗医院收治的96例晚期胃癌患者作为研究对象,按治疗方法不同分为观察组、对照组,各48例。对照组采用XELOX方案治疗,观察组在对照组基础上增加特瑞普利单抗治疗,对比两组患者的临床疗效、肿瘤标志物水平、FOXA2、p27kip1、生活质量评分、治疗安全性。结果观察组患者总有效率为77.08%(37/48),高于对照组的56.25%(27/48),差异有统计学意义(χ^(2)=4.688,P<0.05)。治疗后,观察组癌胚抗原、糖类抗原199、甲胎蛋白水平均低于对照组,差异有统计学意义(P均<0.05);治疗后,观察组FOXA2、p27kip1水平高于对照组,差异有统计学意义(P均<0.05);观察组癌症患者生命质量评分均高于对照组,差异有统计学意义(P均<0.05)。两组患者不良反应发生率对比,差异无统计学意义(P>0.05)。结论特瑞普利单抗联合XELOX方案治疗晚期胃癌效果良好,可降低肿瘤标志物水平,提高FOXA2、p27kip1表达水平,提高患者的生活质量水平,治疗安全性良好。

Objective To investigate the effect of triplelizumab combined with XELOX in the treatment of advanced gastric cancer and the expression levels of recombinant forkhead box protein A2(FOXA2)and Cyclin dependent pro-tein kinase inhibitor(p27kip1).Methods A total of ninety-six patients with advanced gastric cancer admitted to Hon-gqi Hospital Affiliated to Mudanjiang Medical University from January 2022 to December 2023 were non-randomly se-lected as the research objects.According to different treatment methods,they were divided into observation group and control group,with forty-eight cases in each group.The control group was treated with XELOX regimen,and the ob-servation group was treated with triplelizumab on the basis of the control group.The clinical efficacy,tumor marker level,FOXA2,p27 kip1,quality of life score and treatment safety were compared between the two groups.Results The total effective rate of the observation group was 77.08%(37/48),which was higher than 56.25%(27/48)of the con-trol group,and the difference was statistically significant(χ^(2)=4.688,P<0.05).After treatment,the levels of carcinoem-bryonic antigen,carbohydrate antigen 199 and alpha-fetoprotein in observation group were lower than those in control group,and the differences were statistically significant(all P<0.05).After treatment,FOXA2 and p27kip1 levels in the observation group were higher than those in the control group,and the differences were statistically significant(all P<0.05).The quality of life scores of cancer patients in the observation group were higher than those in the control group,and the differences were statistically significant(all P<0.05).There was no significant difference in the inci-dence of adverse reactions between the two groups(P>0.05).Conclusion Triplelizumab combined with XELOX is ef-fective in the treatment of advanced gastric cancer,reduce the level of tumor markers,increase the expression levels of FOXA2 and p27kip1,improve the quality of life of patients,and has good therapeutic safety.